… However, there was almost no published data available for these agents. In contrast, the
single most studied agent we reviewed here was sucralfate, which is a mucosal coating agent. …

… Of the agents studied for the management of OM in this paper, the evidence supports a
Suggestion in favor of topical morphine 0.2% in H&N cancer patients treated with RT-CT for the …

… the panel to suggest against the use of parenteral alanyl-glutamine in cancer patients. …
acid, and vitamin E in 37 pediatric cancer patients in the bone marrow transplantation unit [21]. …

… Athrombogenic coating of CD in cancer patients resulted in a significant reduced necessity
for … with athrombotic coating, we performed a randomised, double-blind trial in cancer patients …

… PEG coated IONPs in terms of in vitro and vivo safety and tested their properties as MRI
contrast agent. More in details, IONPs with core size of 15 nm were synthesized and coated with …

… In the oral route of administration, Eudragit pH-sensitive copolymer as a coating agent
prevents the degradation of the nanoparticle system from the gastric fluid and releases drug to …

… and improving the life quality of cancer patients [8]. However, … system; immunotherapy varies
from patient to patient due to … agents is one of the most effective solutions to treat cancers […

… Same doses of non-coated 3 and coated 3 were used in the current study (50 mg/kg b.wt.;
1/4LD 50 ) and supplemented orally for one month post CCl 4 and the documentation of the …

… The tendency is to include more than one therapeutic agent to accomplish synergistic
anticancer therapies, or to combine drugs with imaging agents for cancer theranostics. The …

… In conclusion, we collected tumor tissues from HNSCC patients, separated the PDTC
membranes, and coated the membranes onto GNPs. By using PDX models, we found the PDTC@…